Intellipharmaceutics International Inc. — Cyborg Score 3/10
Challenged
Specialty pharmaceutical drug delivery systems
Strategic Profile
The company has developed several drug delivery systems based on its technology platform, with a pipeline of products in various stages of development, including ANDA and NDA 505(b)(2) drug product candidates. Products target therapeutic areas including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
Cyborg Score Rationale
The company is experiencing significant financial challenges with minimal revenue generation (approximately $905K as of August 2023) and consistent losses. Stock price has fallen dramatically to penny-stock levels. Limited product commercialization success and uncertain pipeline execution constrain near-term value creation.
Top Insights
Hypermatrix technology platform provides differentiated drug delivery for controlled-release applications across multiple therapeutic areas
Minimal revenue generation ($905K trailing 12 months as of August 2023) despite product approvals indicates commercialization challenges
Stock trading at penny-stock levels ($0.08 CAD as of June 2026) reflects significant investor skepticism
Pipeline includes abuse-deterrent oxycodone and pregabalin extended-release formulations, addressing high-priority FDA initiatives
Named Competitors
Controlled-Release Pharmaceuticals — Specialty generic and controlled-release drug delivery